To compare the prevalence and pattern of comorbid substance use disorders (SUD) between patients with schizophrenia, bipolar disorder, and depressive illness.
Data on presence of alcohol use disorder (AUD) and non-alcohol drug use disorder (DUD) were retrieved from the Norwegian Patient Register for individuals born between 1950 and 1989 who in the period 2009–2013 were diagnosed with schizophrenia, bipolar disorder or depressive illness according to the 10th version of the WHO International Classification of Diseases. The prevalence of AUD only, DUD only, or both was compared between men and women across age and diagnostic groups.
The prevalence of SUD was 25.1 % in schizophrenia (AUD: 4.6 %, DUD: 15.6 %, AUD and DUD: 4.9 %), 20.1 % in bipolar disorder (AUD: 8.1 %, DUD: 7.6 %, AUD and DUD: 4.4 %), and 10.9 % in depressive illness (AUD: 4.4 %, DUD: 4.3 %, AUD and DUD: 2.2 %). Middle-aged men with bipolar disorder had the highest prevalence of AUD (19.1 %) and young men with schizophrenia had the highest prevalence of DUD (29.6 %). Of the specific DUDs, all but sedative use disorder were more prevalent in schizophrenia than the other groups. Cannabis and stimulant use disorder was found among 8.8 and 8.9 %, respectively, of the men with schizophrenia.
The alarmingly high prevalence of DUD among young patients with severe mental disorders should encourage preventive efforts to reduce illicit drug use in the adolescent population.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Negrete JC (2003) Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry 48:14–21
Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K (2004) Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 67:157–166
Turkington A, Mulholland CC, Rushe TM, Anderson R, McCaul R, Barrett SL, Barr RS, Cooper SJ (2009) Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 195:242–248
Cantor-Graae E, Nordström LG, Mcneil TF (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48:69–82
Opsal A, Clausen T, Kristensen O, Elvik I, Joa I, Larsen TK (2011) Involuntary hospitalization of first-episode psychosis with substance abuse during a 2-year follow-up. Acta Psychiatr Scand 124:198–204
Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D (2002) Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 62:743–755
Lagerberg TV, Andreassen OA, Ringen PA, Berg AO, Larsson S, Agartz I, Sundet K, Melle I (2010) Excessive substance use in bipolar disorder is associated with impaired functioning rather than clinical characteristics, a descriptive study. BMC Psychiatry 10:9. doi:10.1186/1471-244X-10-9
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) Study. JAMA 264:2511–2518
Kendler KS, Gallagher TJ, Abelson JM, Kessler RC (1996) Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry 53:1022–1031
Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, Huang B (2005) Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry 66:1205–1215
Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005) Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on alcoholism and related conditions. Arch Gen Psychiatry 62:1097–1106
Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, McGlashan TH (2006) Substance abuse in first-episode non-affective psychosis. Schizophr Res 88:55–62
Nesvåg R, Lange EH, Faerden A, Barrett EA, Emilsson B, Ringen PA, Andreassen OA, Melle I, Agartz I (2010) The use of screening instruments for detecting alcohol and other drug use disorders in first-episode psychosis. Psychiatry Res 177:228–234
Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Jónsdóttir H, Nesvåg R, Vaskinn A, Friis S, Larsen F, Opjordsmoen S, Sundet K, Andreassen OA (2008) Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr Scand 117:133–138
Neale MC, Kendler KS (1995) Models of comorbidity for multifactorial disorders. Am J Hum Genet 57:935–953
Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ (2005) The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry 58:668–676
Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2009) Prevalence of alcohol use disorders in schizophrenia—a systematic review and meta-analysis. Acta Psychiatr Scand 120:85–96
Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36:1115–1130
Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543–552
Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z (2011) Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry 68:241–251
Cerullo MA, Strakowski SM (2007) The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2:29. doi:10.1186/1747-597X-2-29
Kringlen E, Torgersen S, Cramer V (2001) A Norwegian psychiatric epidemiological study. Am J Psychiatry 158:1091–1098
Kringlen E, Torgersen S, Cramer V (2006) Mental illness in a rural area: a Norwegian psychiatric epidemiological study. Soc Psychiatry Psychiatr Epidemiol 41:713–719
Ringen PA, Lagerberg TV, Birkenaes AB, Engn J, Faerden A, Jónsdottir H, Nesvåg R, Friis S, Opjordsmoen S, Larsen F, Melle I, Andreassen OA (2008) Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol Med 38:1241–1249
Di Forti M, Morrison PD, Butt A, Murray RM (2007) Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr Opin Psychiatry 20:228–234
Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, Maccabe JH, Murray RM (2014) Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40:1509–1517. doi:10.1093/schbul/sbt181
Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117
Chambers RA, Krystal JH, Self DW (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50:71–83
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8–19
Berkson J (1946) Limitations of the application of fourfold table analysis to hospital data. Biom Bull 2:47–53
Newman DL, Moffitt TE, Caspi A, Silva PA (1998) Comorbid mental disorders: implications for treatment and sample selection. J Abnorm Psychol 107:305–311
Oiesvold T, Nivison M, Hansen V, Skre I, Ostensen L, Sørgaard KW (2013) Diagnosing comorbidity in psychiatric hospital: challenging the validity of administrative registers. BMC Psychiatry 13:13. doi:10.1186/1471-244X-13-13
Øiesvold T, Nivison M, Hansen V, Sørgaard KW, Østensen L, Skre I (2012) Classification of bipolar disorder in psychiatric hospital. a prospective cohort study. BMC Psychiatry 12:13–14. doi:10.1186/1471-244X-12-13
Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas J, Werge T (2005) Reliability of clinical ICD-10 schizophrenia diagnoses. Nord J Psychiatry 59:209–212
Dalman C, Broms J, Cullberg J, Allebeck P (2002) Young cases of schizophrenia identified in a national inpatient register—are the diagnoses valid? Soc Psychiatry Psychiatr Epidemiol 37:527–531
Ekholm B, Ekholm A, Adolfsson R, Vares M, Osby U, Sedvall GC, Jönsson EG (2005) Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry 59:457–464
Pihlajamaa J, Suvisaari J, Henriksson M, Heilä H, Karjalainen E, Koskela J, Cannon M, Lönnqvist J (2008) The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample. Nord J Psychiatry 62:198–203
This project was funded by the Norwegian Institute of Public Health. We thank Martin Mydske Nilsen for practical support.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Nesvåg, R., Knudsen, G.P., Bakken, I.J. et al. Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol 50, 1267–1276 (2015). https://doi.org/10.1007/s00127-015-1025-2
- Bipolar disorder
- Substance-related disorders